Jacobs Equity LLC Purchases Shares of 12,090 CRISPR Therapeutics AG $CRSP

Jacobs Equity LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,090 shares of the company’s stock, valued at approximately $634,000.

Other large investors have also added to or reduced their stakes in the company. ARK Investment Management LLC increased its position in CRISPR Therapeutics by 7.5% in the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock worth $551,777,000 after purchasing an additional 735,084 shares during the last quarter. Orbis Allan Gray Ltd raised its stake in CRISPR Therapeutics by 19.4% during the fourth quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock valued at $312,026,000 after purchasing an additional 968,060 shares in the last quarter. Capital International Investors lifted its position in CRISPR Therapeutics by 4.3% during the fourth quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after purchasing an additional 243,487 shares during the last quarter. State Street Corp lifted its position in CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after purchasing an additional 859,334 shares during the last quarter. Finally, GSK plc purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth $168,890,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 3,182 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel owned 94,308 shares of the company’s stock, valued at $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the transaction, the chief executive officer owned 255,501 shares of the company’s stock, valued at $11,952,336.78. This trade represents a 3.77% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 16,988 shares of company stock worth $828,167. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Trading Up 1.9%

CRSP stock opened at $54.09 on Friday. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a twelve month low of $43.23 and a twelve month high of $78.48. The stock has a market capitalization of $5.22 billion, a price-to-earnings ratio of -8.70 and a beta of 1.74. The firm’s fifty day simple moving average is $52.68 and its two-hundred day simple moving average is $53.09.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. As a group, analysts anticipate that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a report on Tuesday, March 17th. Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen lowered CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Evercore reissued an “outperform” rating and set a $76.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $67.78.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.